|Bid||1,492.80 x 0|
|Ask||1,492.80 x 0|
|Day's range||1,469.80 - 1,507.00|
|52-week range||1,328.19 - 1,857.00|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||16.08|
|Earnings date||29 Apr 2020|
|Forward dividend & yield||0.92 (6.16%)|
|Ex-dividend date||20 Feb 2020|
|1y target est||1,644.50|
The treatment, Nucala, was tested in patients with a form of chronic rhinosinusitis who had a history of previous surgery and needed further surgery due to severe symptoms or worsening of the condition, the British drugmaker said. The study met both main goals and showed that Nucala(mepolizumab), which is administered using a pre-filled syringe, when added to standard of care led to statistically significant improvements in both the size of nasal polyps and in nasal obstruction compared to the placebo arm, GlaxoSmithKline said.
Wake up ISA investors! This bargain dividend income stock could be the best buy on the FTSE 100 (INDEXFTSE:UKX) as stock markets crash.The post Forget gold and Bitcoin. I'd buy this FTSE 100 dividend bargain in an ISA as stock markets crash appeared first on The Motley Fool UK.
Peter Stephens thinks these two FTSE 100 (INDEXFTSE:UKX) stocks could offer attractive long-term returns.The post As the stock market crash continues, I’d buy these 2 bargain FTSE 100 shares in an ISA appeared first on The Motley Fool UK.
We asked our freelance writers to share their top British shares for April, including Rightmove, Diageo and Tritax Big Box REIT.The post Top British shares for April 2020 appeared first on The Motley Fool UK.
An opportunity that may be too good to pass up in the form of a FTSE 100 champion!The post Here is a FTSE 100 stock I would consider in the market crash appeared first on The Motley Fool UK.
FTSE 100 investors need look no further than Warren Buffett. Here the world's richest investor tells you exactly what to look for in troubled times. The post FTSE 100 choppy after crash: What would Warren Buffett buy? appeared first on The Motley Fool UK.
(Bloomberg Opinion) -- If we want a vaccine or drug treatment to stop coronavirus, the government should ignore those complaining about drug-company profits and commit to a huge reward that encourages more businesses to develop one. It wouldn’t just save lives; it could save the global economy. The coronavirus could cost the U.S. $1.5 trillion in annual economic output, or $125 billion every month — and that’s a conservative estimate. The losses for the entire world economy will be four to five times larger. And these economic costs will be dwarfed by the human costs of illness and death. Absent a vaccine or treatment, this pandemic will likely be with us for more than a year. Speeding the development of vaccines and effective drug therapies by vastly increasing the rewards for businesses would decisively limit the economic damage. Based on the economic losses in the U.S. alone, the government should be willing to spend at least an additional $62.5 billion to spur Covid-19 research and development. Even if that shortened the crisis by just two weeks, it would be a bargain. Research teams at large pharma companies such as Roche, Eli Lilly, Sanofi Pasteur and Takeda, and smaller biotech firms such as BioNTech, are racing to develop a vaccine. But these firms stand to capture only a small fraction of the large economic benefit that will accrue to society when they successfully produce a vaccine or therapy. Developers will likely be pressured to offer a future vaccine at a low price. Even now, there have been calls to sharply limit future profits from such a vaccine. The result is significant underinvestment in the development of vaccines that will likely have large social benefits. Here is a simple way to see this. U.S. spending on all pharmaceutical R&D in 2020 was projected to be $80 billion — equivalent to three weeks of the annual U.S. economic output loss — with only a small fraction of this directed toward infectious diseases. In 1967, 26 pharmaceutical companies produced vaccines; by 1980, 17 did; only four — GlaxoSmithKline, Merck, Pfizer and Sanofi Pasteur — undertake significant production today. This is not surprising. Developing a vaccine requires $500 million to $1 billion in investment, recent estimates suggest, while only 7% of projects result in a vaccine. As a result, even today, with the pandemic raging, many small biotech firms are watching from the sidelines. Those working on vaccines rely on money from foundations and government initiatives. Two of the most promising developers of a Covid-19 vaccine, Inovio and Moderna, are funded by the Coalition for Epidemic Preparedness Innovations (Cepi), an alliance of charities and governments. The U.S. government, perhaps working with others, should guarantee a significant financial payment to whoever first develops a vaccine. One way to do this would be to commit to a high price for each administered dose of an effective vaccine or treatment therapy. As an example, if the U.S. government were to promise a price of $190 per administered dose to the developers, spending a maximum of $62.5 billion to vaccinate or treat all Americans, then society would have earned back its investment even if this only sped up the development by two weeks. The vaccine should also be made available at marginal cost to developing countries.The government could further stimulate collaboration by committing to large awards for successful clinical trials, provided that the research is fully disclosed. If the European Union were to make a similar commitment to this price per administered dose, the total incentives could be strengthened by another $100 billion. While creating vaccines always takes time, experts in the field have learned from previous episodes that there can be major bottlenecks in vaccine development and manufacturing. Once developed, the supply is likely to fall short of demand for a long period. Additional financial resources can relieve these production bottlenecks. We are not asking the U.S. government, or any other government, to pick winners. We are asking the government to make an ironclad commitment right now, backed by legislation, to reward those companies that successfully lead the fight against Covid-19 and future outbreaks.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Hanno Lustig is a professor of finance at Stanford University. Jeffrey Zwiebel is a professor of finance at Stanford University. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Jonathan Smith explains why he is eyeing up both GlaxoSmithKline and Pennon Group for his 2020 ISA allocation.The post Don't miss the ISA deadline! Here's 2 FTSE 100 stocks I'm keen to buy for my 2020 ISA allocation appeared first on The Motley Fool UK.
Don't let the FTSE 100 crash scare you off. Buying now could help you beat the market over the next 10 years, says Roland Head.The post Don't waste the stock market crash! FTSE 100 shares I'd buy for the next 10 years appeared first on The Motley Fool UK.
FTSE 100 company GlaxoSmithKline is firmly on this Fool's radar!The post If I could buy only 1 FTSE 100 share in this market crash, it'd be this appeared first on The Motley Fool UK.
Most shares are now cheaper than they were just a month ago and Andy Ross thinks these FTSE 100 shares are particularly good value. The post These 2 FTSE 100 shares look cheap to me. I'd buy them in this market crash appeared first on The Motley Fool UK.
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
The FTSE 100 (INDEXFTSE: UKX) index offers many robust dividend shares that are likely to catch the attention of passive income seekers.The post 2 FTSE 100 dividend shares I’d consider now appeared first on The Motley Fool UK.
These defensive FTSE 100 income stocks look too cheap to pass up after recent declines, says Rupert Hargreaves. The post I'd use the stock market crash to snap up these two FTSE 100 4%-yielders appeared first on The Motley Fool UK.
This FTSE 100 pharmaceuticals ace has dived over the past few weeks. But Royston Wild explains why it remains a top pick for long-term investors.The post Is this FTSE 100 dividend stock a ‘best buy’ in this stock market crash? appeared first on The Motley Fool UK.
Emma Walmsley has been the CEO of GlaxoSmithKline plc (LON:GSK) since 2017. This report will, first, examine the CEO...
Here are two resilient FTSE 100 stocks with big dividend yields at the top of my watch list.The post 2 top FTSE 100 shares I’d buy right now despite the market sell-off appeared first on The Motley Fool UK.
Long-term investors like Warren Buffett should consider these FTSE 100 (INDEXFTSE: UKX) dividend stocks, says Roland Head.The post 3 FTSE 100 stocks I think Warren Buffett would buy in this market crash appeared first on The Motley Fool UK.
Knowing how to steer clear of disastrous investments is just as valuable as picking winners - this is why legendary investors such as Seth Klarman always advis8230;
Germany's Merck KGaA said adjusted core earnings would see "strong" growth, excluding the effect of currency swings, driven by its prescription drugs unit and the lab equipment business. The company said that while the impact of the current coronavirus epidemic was difficult to determine, it was currently working on the assumption that the outbreak would reach its high point in the first quarter and subside during the second.
The Trump administration said on Monday it had secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus. At a meeting with industry executives at the White House, President Donald Trump exhorted the companies to collaborate to speed the process of getting a vaccine and therapeutics to victims of the virus. The White House, which has clashed previously with the pharmaceutical industry over high drug prices and has been struggling in recent weeks to show it is on top of the virus response, saw the meeting as a victory.
These FTSE 100 income stocks have fallen in value, but their long-term outlook has only improved. The post £5k to invest? Here are 2 FTSE 100 dividend stocks I'd buy right now appeared first on The Motley Fool UK.
These FTSE 100 (INDEXFTSE: UKX) stocks offer value and safety, reckons Roland Head.The post 3 FTSE 100 dividend stocks I'd buy with my last £1k appeared first on The Motley Fool UK.
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.